Receptor-Negative Phenotypes and Dose-Limiting Off-Target Cytotoxicity
Receptor-negative breast malignant neoplasms, primarily triple-negative breast cancer (TNBC), lack human epidermal growth factor receptor 2 (HER2) amplification as well as estrogen and progesterone receptor expression [1]. This negative phenotypic profile renders endocrine regimens and HER2-directed monoclonal antibodies completely ineffective, leaving cytotoxic anthracycline-based chemotherapy as the principal pharmacological strategy [1][2]. Doxorubicin, an anthracycline antibiotic, functions primarily via planar intercalation into nuclear duplex DNA and stabilization of topoisomerase II cleavage complexes, resulting in lethal DNA double-strand breaks [2][3]. The clinical success of native, unencapsulated doxorubicin is strictly compromised by life-threatening off-target toxicities, most prominently cumulative, irreversible dilated cardiomyopathy and congestive heart failure [2][3].
Cardiomyocyte attrition stems from doxorubicin binding to Topoisomerase IIβ isoforms present in non-proliferating myocardium [2]. This aberrant interaction triggers mitochondrial outer membrane permeabilization, dysregulates intracellular iron homeostasis, and initiates continuous redox cycling that generates elevated levels of superoxide anions and hydroxyl radicals [1][3]. Free doxorubicin exhibits an extensive steady-state volume of distribution ranging between 700 and 1100 L/m², driven by unrestricted passive diffusion across biological membranes and non-selective binding to normal tissue proteins [2]. Consequently, only a tiny fraction of the administered drug dose reaches malignant mammary tissues. As summarized in Table 1, free anthracyclines exhibit suboptimal selectivity indices, rapid systemic elimination, and substantial off-target cardiotoxicity compared to macromolecular and nanocarrier platforms. Developing targeted delivery architectures that restrict native distribution, protect non-malignant cardiac tissues, and concentrate the chemotherapeutic agent within malignant lesions remains essential [4]. Crosslinking doxorubicin into hydrophilic hyaluronic acid architectures represents an effective platform to overcome these non-specific tissue distribution profiles [4].
CD44-Receptor Architecture and Endocytic Internalization Kinetics
Malignant breast carcinoma populations, particularly basal-like and mesenchymal TNBC variants, show marked upregulation of the cell-surface adhesion glycoprotein CD44 [4][5]. CD44 expression correlates with advanced histological grade, aggressive metastatic progression, and enriched stem-like characteristics [4][5]. The primary endogenous ligand for CD44 is hyaluronic acid (HA), a non-sulfated glycosaminoglycan consisting of alternating D-glucuronic acid and N-acetyl-D-glucosamine residues [4][5]. Low-to-medium molecular weight hyaluronic acid polymers (10 to 50 kDa) engage the extracellular amino-terminal hyaluronan-binding domain of both standard (CD44s) and variant (CD44v) isoforms with high avidity, yielding dissociation constants (Kd) in the nanomolar range [4].
Conjugation of doxorubicin to hyaluronic acid matrices redirects cellular entry away from non-selective passive lipophilic diffusion toward CD44-dependent endocytosis [4][6]. In receptor-overexpressing models such as MDA-MB-231 and Hs 578T, exposure to hyaluronic acid nanoparticle formulations triggers rapid invagination of the plasma membrane via clathrin-coated pits [6]. Quantitative uptake assays show that hyaluronic acid carrier assemblies undergo vesicular internalization within 30 to 90 minutes post-exposure, whereas CD44-deficient MCF-7 cells exhibit minimal nanoparticle ingestion under equivalent incubation conditions [4]. Pre-treatment of CD44-rich cells with excess unlabelled hyaluronic acid or anti-CD44 blocking antibodies significantly diminishes intracellular doxorubicin concentrations, verifying target-dependent receptor uptake [4]. Once internalized, the receptor-ligand complex transitions from clathrin-coated vesicles to early Rab5-positive endosomes, initiating a regulated subcellular sorting process that protects extracellular tissues from exposure to the free anthracycline [4][6].
Acid-Labile Linker Chemistry and Endolysosomal Payload Discharge
The systemic stability and intracellular activation of hyaluronic acid-doxorubicin assemblies are governed by the chemical linkages bridging the hydrophilic polysaccharide backbone to the anthracycline core [2][5]. Direct covalent attachment frequently utilizes acid-labile bridges, such as hydrazone, ester, or cis-aconityl bonds, engineered between the C-13 carbonyl moiety or C-14 hydroxyl position of doxorubicin and the carboxylate groups of hyaluronic acid [2]. In physiological vascular conditions (pH 7.4), these covalent linkages remain structurally stable, suppressing premature esterase or hydrolytic cleavage during systemic circulation and preventing untimely anthracycline discharge into plasma [2][5].
Following endocytic uptake, vesicular acidification proceeds rapidly as the early endosome matures into late endosomes and lysosomes [5][6]. Vacuolar-type H+-ATPase proton pumps lower the intraluminal pH from 6.5 to an acidic 4.5 to 5.5 [5]. Protonation of the acid-sensitive hydrazone or ester bond accelerates linker cleavage, releasing native, unmodified doxorubicin into the endolysosomal lumen within hours of internalization [2][5]. The hydrophobic aglycone core of unlinked doxorubicin then diffuses across the endosomal membrane into the neutral perinuclear cytoplasm, where it binds importin proteins or diffuses across nuclear pores [5][6]. Inside the nucleus, the released doxorubicin intercalates into 5'-d(CpG)-3' genomic dinucleotide sequences and traps Topoisomerase IIα, generating locked covalent ternary complexes [2]. This entrapment halts DNA replication fork advancement and drives the formation of high-density phosphorylated histone γ-H2AX double-strand breaks, triggering programmed apoptotic cascades without premature systemic exposure [4][6].
Circumvention of ABCB1-Mediated Efflux in Anthracycline-Resistant Tumors
Acquired and intrinsic chemoresistance severely limits the long-term effectiveness of systemic doxorubicin regimens in receptor-negative breast cancer [1][3]. A central driver of this refractory phenotype is the upregulation of ATP-binding cassette (ABC) transporter proteins, primarily ABCB1 (also known as P-glycoprotein or MDR1) [5]. ABCB1 functions as an ATP-dependent efflux pump located in the plasma membrane, directly binding hydrophobic, neutral or positively charged xenobiotics present within the lipid bilayer and pumping them out into the extracellular space [5]. Because free doxorubicin enters cells via passive transmembrane partitioning, it encounters ABCB1 directly within the lipid bilayer, resulting in continuous efflux, reduced steady-state intranuclear drug levels, and compromised therapeutic responses [5][6].
Macromolecular hyaluronic acid nanoparticles evade this plasma-membrane efflux machinery by internalizing through endocytic vesicle engulfment [5][6]. Nanoparticles do not partition into the lipid bilayer where ABCB1 substrate recognition occurs; instead, they traverse the membrane enclosed inside endosomes and deposit their cargo within the perinuclear space [6]. In resistant breast cancer models such as MCF-7/ADR, cellular uptake of nanoparticle-encapsulated formulations is up to 21-fold higher than that of free doxorubicin [5]. Cytotoxicity profiling reveals an 8- to 15-fold downward shift in the half-maximal inhibitory concentration (IC50) when multi-drug resistant cells are treated with nanoparticle delivery systems relative to the unencapsulated anthracycline [5][6]. Nanoparticle-mediated delivery also depletes the CD44-positive cancer stem cell compartment, downregulating Notch1 and Ras/MAPK signaling cascades to suppress clonogenic survival and inhibit secondary tumor seeding [4][7].
Comparative Pharmacodynamics and Cardioprotective Biodistribution Profiles
Nanoscale delivery systems drastically alter the pharmacokinetic disposition of doxorubicin in vivo [7]. Free doxorubicin is cleared rapidly from the bloodstream, displaying a terminal elimination half-life (t1/2β) of 1 to 3 hours in rodents and approximately 30 hours in humans, driven by rapid distribution into non-target tissues and extensive hepatic metabolism [2][7]. Formulating the anthracycline into hyaluronic acid nanocarriers or protective cages extends circulation time, prolonging the elimination half-life by 4- to 7-fold while lowering systemic clearance rates [7]. This prolonged intravascular residence facilitates passive accumulation within solid tumors through leaky tumor microvasculature, complemented by active CD44-mediated cellular uptake [4][7].
Quantitative biodistribution evaluations in aggressive 4T1 breast cancer orthotopic models demonstrate that macromolecular carriers alter tissue selectivity indices [7]. Peak drug accumulation in healthy cardiac tissues is reduced by more than 60% relative to equivalent systemic doses of free doxorubicin [7]. Decreased cardiac exposure correlates with normal serum cardiac troponin I (cTnI) and brain natriuretic peptide (BNP) concentrations, and histopathological examination shows preserved myocardial myofibrillar structure without vacuolization [7][8]. Orthotopic tumor xenografts treated with targeted formulations display marked suppression of tumor growth, extensive terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positivity, and diminished metastatic lung seeding [4][7]. These outcomes confirm that hyaluronic acid-crosslinked nanostructures overcome the narrow therapeutic window of native anthracyclines, delivering potent targeted antitumor activity while safeguarding vital cardiac tissues [4][7][8].